Publicaciones científicas

/cun/investigacion/publicaciones-cientificas/areaMain/02
  • One-Year Results for Patients with Unilateral Hearing Loss and Accompanying Severe Tinnitus and Hyperacusis Treated with a Cochlear Implant

    Ramos Macías A (1), Falcón-González JC (1), Manrique Rodríguez M (2), Morera Pérez C (3), García-Ibáñez L (4), Cenjor Español C (5), Coudert-Koall C (6), Killian M (6).

    (1) Unidad de Hipoacusia, Servicio de Otorrinolaringología, Complejo Hospitalario Universitario Insular Materno Infantil, Las Palmas, Spain.
    (2) Servicio de Otorrinolaringología, Clínica Universitaria de Navarra, Pamplona, Spain.
    (3) Servicio de Otorrinolaringología, Hospital Universitario La Fe, Valencia, Spain.
    (4) Servicio de Otorrinolaringología, Instituto de Otologia Garcia Ibanez, Barcelona, Spain.
    (5) Servicio de Otorrinolaringología, Fundacion Jimenez Diaz, Madrid, Spain.
    (6) Cochlear EMEA, Basel, Switzerland.

    Audiology & Neuro-otology 21 de JUNIO de 2018

  • Oral immunotherapy using polymeric nanoparticles loaded with peanut proteins in a murine model of fatal anaphylaxis

    Gamazo C (1), García-Azpíroz M (1), Souza Rebouças J (1,2), Gastaminza G (3), Ferrer M (3), Irache JM (4). (1) Department of Microbiology, University of Navarra, Instituto de Investigación Sanitaria de Navarra (Idisna), C/Irunlarrea, 1; 31080 - Pamplona, Spain.
    (2) Laboratory of Microbiology & Immunoregulation, Gonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil.
    (3) Department of Allergology & Clinical Immunology, Clínica Universidad de Navarra, Navarra, Spain.
    (4) Department of Pharmacy & Pharmaceutical Technology, University of Navarra, Navarra, Spain.

    Immunotherapy 09 de NOVIEMBRE de 2017

  • Obesity phenotypes and their paradoxical association with cardiovascular diseases

    Vecchié A (1), Dallegri F (2), Carbone F (1), Bonaventura A (1), Liberale L (3), Portincasa P (4), Frühbeck G (5), Montecucco F (6). (1) First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy.
    (2) First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy; Ospedale Policlinico San Martino, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, 10 Largo Benzi, 16132 Genoa, Italy.
    (3) First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy; Centre for Molecular Cardiology, University of Zürich, 12 Wagistrasse, 8952 Schlieren, Switzerland.
    (4) Clinica Medica "A. Murri", Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro" Medical School, Bari, Italy.
    (5) Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Spain; Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (6) First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy; Ospedale Policlinico San Martino, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, 10 Largo Benzi, 16132 Genoa, Italy; Centre of Excellence for Biomedical Research (CEBR), University of Genoa, 9 viale Benedetto XV, 16132 Genoa, Italy.

    European Journal of Internal Medicine 31 de OCTUBRE de 2017

  • Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells

    Serrano-Candelas E (1,2), Martínez-Aranguren R (3), Vega O (3), Gastaminza G (3), Bartra J (4), Audicana MT (5), Núñez-Córdoba JM (6), Algorta J (7), Valero A (4,8), Martin M (9,10), Ferrer M (11). (1) Biochemistry Unit, Faculty of Medicine, University of Barcelona, Casanova 143, Barcelona, 08036, Spain.
    (2) Laboratory of Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain.
    (3) Department of Allergy and Clinical Immunology, Clinica Universidad de Navarra, Pamplona, Spain.
    (4) Department of Pneumology and Allergology, Immunoallèrgia Respiratòria Clínical Experimental, IDIBAPS, Hospital Clínic, Barcelona, Spain.
    (5) Allergy Service, Hospital Santiago, Vitoria, Spain.
    (6) Research Support Service, Central Clinical Trials Unit, Clinica Universidad de Navarra, Pamplona, Spain.
    (7) Department of Biochemistry and Molecular Biology, Universidad del Pais Vasco-EHU, Bizkaia, Spain.
    (8) Centro de Investigación Biomédica en Red de Enfermedades Respiratorias [Biomedical Research Networking Centre on Respiratory Diseases (CIBERES)], Madrid, Spain.
    (9) Biochemistry Unit, Faculty of Medicine, University of Barcelona, Casanova 143, Barcelona, 08036, Spain.
    (10) Laboratory of Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain.
    (11) Department of Allergy and Clinical Immunology, Clinica Universidad de Navarra, Pamplona, Spain.

    Scientific Reports 21 de AGOSTO de 2017

  • Occult cancer screening in patients with venous thromboembolism: guidance from the SSC of the ISTH

    Delluc A (1), Antic D (2), Lecumberri R (3), Ay C (4), Meyer G (5), Carrier M (6). (1) EA 3878, Department of Internal Medicine and Chest Diseases, Centre hospitalier universitaire de Brest, Hôpital de la Cavale Blanche, Brest, France.
    (2) Clinic for Hematology, Lymphoma Center, Clinical Center Serbia, Medical Faculty, Department for Internal Medicine, University of Belgrade, Belgrade, Serbia.
    (3) Hematology Service, Clínica Universidad de Navarra, Pamplona, Spain.
    (4) Department of Medicine I, Clinical Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
    (5) Department of Respiratory Disease, Hôpital Européen Georges Pompidou, Université Paris Descartes, Sorbonne Paris Cité, INSERM UMRS 970 and CIC 1418, Paris, France.
    (6) Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.

    Journal of Thrombosis and Haemostasis 04 de AGOSTO de 2017

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra